ViroPharma, Inc. (NASDAQ:VPHM)

CAPS Rating: 3 out of 5

A biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases, with a focus on products used by physician specialists or in hospital settings.

Recs

1
Player Avatar MagicDiligence (< 20) Submitted: 8/13/2010 9:18:35 AM : Outperform Start Price: $13.15 VPHM Score: +57.42

ViroPharma markets two drugs: Vancocin for clostridium difficile infections, and Cinryze for rare hereditary angioedema. The company's investment potential is tied to how fast the latter can replace declining sales from the former.Read my full CAPS review here:http://caps.fool.com/Blogs/viropharma-vphm-a-tale-of/433135

Featured Broker Partners


Advertisement